The first Greek patients with metastatic pancreatic cancer have already received daraxonrasib, a new targeted therapy, entirely free of charge, roughly two and a half months after the US Food and Drug Administration approved it on August 26, 2026.
Access came through IFET, the Institute of Pharmaceutical Research and Technology, which is Greece's national public pharmaceutical wholesaler. IFET can supply medicines to patients before they are formally marketed or reimbursed in Greece, and even before the European Commission issues its final marketing authorisation for the EU.
The European Medicines Agency's Committee for Medicinal Products for Human Use issued a positive opinion on the drug on October 15, following a rapid, stepwise assessment. The European Commission's formal decision is still pending, making Greece one of the very first countries in Europe to get the treatment into patients' hands.
Aris Angelis, head of the Ministry of Health's health technology assessment committee and former secretary-general for Strategic Planning at the ministry, confirmed the development, saying the treatment is being provided free to the patients who need it. He posted on LinkedIn a day after Health Minister Adonis Georgiadis announced it on X, congratulating IFET head Eleftheria Tokatlidi and the minister for the speed of access.
Angelis also noted that early access mechanisms like this one cannot be sustained on their own. He said it is necessary to build fiscal space within the broader healthcare system by prioritising treatments that show real clinical value, pointing to the structural challenge behind what is otherwise a clear win for Greek patients.
Daraxonrasib targets a mutation present in the vast majority of pancreatic cancers and more than doubled median survival compared to standard chemotherapy in clinical trials, from roughly 6.7 months to 13.2 months.
#Greece #PancreaticCancer #HealthNews
The first Greek patients with metastatic pancreatic cancer have already received daraxonrasib, a new targeted therapy, e...
Written on 11/22/2026